Pipeline

Companion Diagnostics (CDx)

We are developing quantitative immunofluorescent, or QIF companion diagnostic assays using our proprietary monoclonal antibodies, that predict how well a cancer patient is likely to respond to treatment with RTK inhibitors and anti-microtubule drugs.

Not everyone responds in the same way to these treatments. Patients with tumors expressing high levels of Mena develop resistance to treatment with RTK inhibitors (EGFR, HGFR and IGF-R1 inhibitors) and anti-microtubule drugs (docetaxel, paclitaxel and albumin-bound paclitaxel).

Our companion diagnostics aim to help oncologists refine diagnosis and tailor treatment strategies, saving patients precious time and expense by predicting response to these therapies prior to administration.